NGM Bio Presents Positive Phase 2b Results from the ALPINE 4

13.11.2023 - -As previously reported, the ALPINE 4 study met its primary endpoint, with aldafermin 3 mg demonstrating a statistically significant reduction in Enhanced Liver Fibrosis (ELF) score compared to placebo after 48 weeks of treatment- -ELF, an ... Seite 1

Related Keywords

Marye Rinella , , University Of Chicago Pritzker School Medicine , Steatotic Liver Disease Program , Biopharmaceuticals Inc , American Association , Liver Diseases , Trial Evaluating Multiple Doses , Compensated Cirrhosis Due , Nonalcoholic Steatohepatitis , Liver Meeting , Chicago Pritzker School , Ngm Biopharmaceuticals Chart , Gm Biopharmaceuticals Kurs , Gm Biopharmaceuticals Aktie ,